The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are α-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
The present invention relates to a hybrid material comprising a perovskite and a singlet fission compound. The hybrid material comprises layers of the perovskite in which the singlet fission compound occupies an interlayer space of the perovskite structure. The hybrid material may be useful as a semiconductor, e.g., in a photovoltaic cell. Also disclosed are processes for preparing the hybrid material and components comprising the hybrid material, such as a photovoltaic cell.
C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead
H01L 31/0248 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies
3.
HIGH-TEMPERATURE SUPERCONDUCTING SWITCHES AND RECTIFIERS
There is provided a rectifier of an alternating input current, which may comprise: an electrical switch comprising a length of HITS material to carry an alternating switch current, the HITS material having a critical current: a magnetic field generator to apply a magnetic field to the HTS material: a control mechanism to control the magnetic field generator to switch the switch between a low-resistance state when a magnitude of the magnetic field is relatively low and a higher-resistance state when a magnitude of the magnetic field is relatively high, the relatively high magnitude being sufficient to reduce the critical current so that, for a part of the alternating switch current cycle, the current approaches the critical current, is substantially equal to the critical current or is greater than the critical current. There is further provided an electrical switch having two strands of superconducting material arranged in a bifilar arrangement.
H03K 17/92 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the use of specified components by the use, as active elements, of superconductive devices
H01F 7/06 - ElectromagnetsActuators including electromagnets
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV):
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV):
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
5.
IMPROVEMENTS IN CONTROL OF CURRENT SUPPLY TO A TRANSFORMER-RECTIFIER FLUX PUMP
The technology relates to the field of superconductor transformer-rectifier flux pumps and controlling a supply of alternating current to a transformer-rectifier flux pump to charge a load. A response of the transformer-rectifier flux pump to a characterisation current supply is determined, which may comprise determining values in the flux pump corresponding to values of the applied current. For each of a plurality of target values of load current to be supplied to the load, values of the current supply are calculated. The supply of current to the flux pump is controlled accordingly. The supply may be modified based on feedback received from the flux pump, for example sensors measuring values on the secondary side of the transformer.
H01F 27/40 - Structural association with built-in electric component, e.g. fuse
H01F 41/04 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformersApparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets for manufacturing coils
H01H 36/00 - Switches actuated by change of magnetic field or of electric field, e.g. by change of relative position of magnet and switch, by shielding
H02H 7/00 - Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions
H02M 7/02 - Conversion of AC power input into DC power output without possibility of reversal
The present invention relates to improvements in scanning electrochemical microscopy. The device includes a probe configured with two barrels: the first barrel configured to hold a liquid solution and a probe electrode; and the second barrel configured to hold a gas and an inlet connectable to a gas supply. The probe is shaped into a scanning tip formed at distal ends of the first and second barrels, and the device may further include a gas controller to control pressure and/or flow rate of the gas to the second barrel of the probe. The device may further include a reference electrode configured for use in the liquid solution, and a counter electrode configured for use in the liquid solution.
Some previously proposed technologies may not quickly and effectively locate and manage faults in an electricity network, such as high impedance faults. Disclosed herein is a method for determining a fault location in an electricity distribution network. Such a method may comprise receiving one or more electrical signals (e.g. voltage or current signals) obtained from one or more measurement locations at the electricity distribution network. The one or more electrical signals may have been influenced by a fault at the network. The method may decompose each electrical signal to derive one or more constituent frequency components. Such constituent frequency components may be constructable to approximate (or estimate) the electrical signal. The method may provide a circuit model of a portion of the electricity distribution network. Such circuit model may comprise an expected fault location. The method may establish one or more predicted relationships between the fault location and the electrical signals using the circuit model. The method may derive one or more estimated fault locations to determine the fault location in the electricity distribution network. The method may derive each estimated fault location from a predicted relationship using a constituent frequency component decomposed from each of the respective electrical signals in the predicted relationship.
G01R 27/16 - Measuring impedance of element or network through which a current is passing from another source, e.g. cable, power line
G01R 27/28 - Measuring attenuation, gain, phase shift, or derived characteristics of electric four-pole networks, i.e. two-port networksMeasuring transient response
Aspects of the technology provide a method / system of sensing a change in temperature and/or strain in an optical fibre comprising a substantially continuous or quasi-continuous fibre Bragg grating. A difference spectrum is determined between a reference reflected spectrum of the fibre Bragg grating and a monitored reflected spectrum. The difference spectrum is analysed to determine whether the optical fibre is experiencing a change of type a) – a temperature increase or an extension – or of type b) – a temperature decrease or a contraction. The technology may be applied to sensing a change in temperature and/or strain in a superconductor or detecting a risk of a quench in a superconductor.
G01K 11/3206 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres at discrete locations in the fibre, e.g. using Bragg scattering
G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
G01D 1/16 - Measuring arrangements giving results other than momentary value of variable, of general application giving a value which is a function of two or more values, e.g. product or ratio
G01D 5/26 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using optical means, i.e. using infrared, visible or ultraviolet light
There is provided an electrical switch comprising a length of superconducting material. In some forms the electrical switch is configured to be controlled between a low-resistance state and a higher-resistance state by the selective application of one or more switching mechanisms. In the higher-resistance state, current flowing through the length of superconducting material may approach the critical current of the length of superconducting material, may be substantially equal to the critical current or may be greater than the critical current. In some forms, the length of superconducting material is a length of high temperature superconducting material. The switching mechanisms may comprise: heating the length of superconducting material; applying a magnetic field to the length of superconducting material; applying a time-varying magnetic field to create dynamic resistance and/or heat; and/or applying a time-varying magnetic field to a loop of superconducting material to create a screening current around the loop.
The invention relates to a device for inducing a current flow in a load, also referred to as a flux pump. The device may comprise a rotor comprising at least one magnetic field generator configured to rotate with the rotor, one or more lengths of superconducting material arranged as an induction coil, a switch, and output terminals configured to connect to a load, the output terminals being connected in parallel with the switch. Rotation of the rotor may move the at least one magnetic field generator relative to the induction coil and switch, such that the magnetic field is periodically applied to the induction coil and switch to induce a current flow in the induction coil through the switch, and to reduce a critical current of the material within the switch, causing the switch to transition from a low-resistance state to a higher-resistance state.
G01R 33/3815 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets with superconducting coils, e.g. power supply therefor
The technology relates to electrical devices comprising a length of superconducting material with a critical current when current travels in one direction is different to a critical current of the length of superconducting material when current travels through the length of superconducting material in an opposite direction. The electrical device may further comprise a magnetic field generator comprising two permanent magnets positioned on the same side of the length of superconducting material and arranged substantially anti-parallel to each other. The polar axes of the two permanent magnets may be oriented substantially perpendicular to the faces of the length of superconducting material.
H03K 17/92 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the use of specified components by the use, as active elements, of superconductive devices
H03K 19/195 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using superconductive devices
C12N 15/80 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
14.
AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are a-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Biosensor systems for detecting levels of nitrogen-containing molecules are provided. Further provided are biosensor system components and various detection platforms, methods, and kits.
C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
17.
RNA LIGASE ENZYMES AND METHODS OF PREPARATION AND USE THEREOF
The present disclosure encompasses RNA ligase enzymes, particularly thermostable RNA ligase enzymes, and including variant enzymes, along with the preparation and use thereof. Specifically encompassed are methods for preparing the RNA ligase enzymes, methods for ligation using these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
C07H 15/18 - Acyclic radicals, substituted by carbocyclic rings
C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
A method for generating a saliency map for use in polygon reduction, including: processing a 3D object file of an object by storing vertices of meshes of the object in a data structure; determining a tropical angle of curvature for each vertex within a geodesic radius, wherein the tropical angle of curvature represents a difference in angles of normal vectors at all vertices connected to the vertex by a mesh edge; and generating a saliency value for each vertex for the saliency map based on the tropical angle of curvature.
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.
Disclosed are a cathode materials suitable for an aluminium ion battery, wherein the cathode materials comprise a main group element nitride, and an oxide of a main group element or an oxide of a element in Group 1 to 13. The nitride is preferably a 2-dimensional layered material. Preferably, the ratio of the main group element nitride to the oxide is between 5:95 and 95:5 (by weight).
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
H01M 4/46 - Alloys based on magnesium or aluminium
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 50/46 - Separators, membranes or diaphragms characterised by their combination with electrodes
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
A polymer composition for impregnating a high temperature superconductor (HTS) coil, the composition comprising: a polymer resin, a plurality of particles of a first filler material, and a plurality of particles of a second filler material; wherein the median particle size of the second filler material is less than the median particle size of the first filler material. The polymer composition may be used to prepare a polymer impregnated HTS coil having a predetermined turn-to-turn spacing. A property of the polymer composition may also be modified, for example, the coefficient of thermal contraction and/or resistivity of the composition. Also disclosed is a polymer impregnated HTS coil and a method for preparing the coil.
Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing an infection caused by Human Cytomegalovirus (HCMV), Epstein-Barr virus (EBV), or Human Immunodeficiency Virus (HIV).
A61P 31/22 - Antivirals for DNA viruses for herpes viruses
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))
The invention relates to a combination of a TLR-9 agonist and a conjugate of Formula (I) or pharmaceutically acceptable salt thereof. (Formula (I))
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention encompasses non-ribosomal peptides and non-ribosomal peptide synthetases, and the preparation and use thereof. Specifically encompassed are methods for preparing non-ribosomal peptide synthetases, methods for preparing non-ribosomal peptides from these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
The invention relates to a stabilising head support for use by a patient during MRI scanning. The head support includes a shell and an inflatable bladder that is located at least partially within the shell. During use, the shell is located within an MRI magnet and the bladder is inflated about the patients head to help hold the head steady during imaging.
Described herein is a process for hydroarylation of an olefin to obtain an alkylated benzene product. The process involves reacting an olefin compound of formula II with an arene compound of formula III in the presence of a lanthanide complex, e.g. a lanthanide (II) hydride complex. Also described herein is a lanthanide complex and process for the preparation thereof.
The present disclosure relates to the field of medical applications. In particular, to a measurement system and method for non-invasive detection and monitoring of physiological parameters, in particular perfusion, to provide clinically relevant information through Nuclear Magnetic Resonance (NMR) observation.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
There is provided a rectifier of an alternating input current, which may comprise: an electrical switch comprising a length of HTS material to carry an alternating switch current, the HTS material having a critical current; a magnetic field generator to apply a magnetic field to the HTS material; a control mechanism to control the magnetic field generator to switch the switch between a low-resistance state when a magnitude of the magnetic field is relatively low and a higher-resistance state when a magnitude of the magnetic field is relatively high, the relatively high magnitude being sufficient to reduce the critical current so that, for a part of the alternating switch current cycle, the current approaches the critical current, is substantially equal to the critical current or is greater than the critical current. There is further provided an electrical switch having two strands of superconducting material arranged in a bifilar arrangement.
H02M 5/293 - Conversion of AC power input into AC power output, e.g. for change of voltage, for change of frequency, for change of number of phases without intermediate conversion into DC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
H02M 7/217 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
H02M 7/48 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode
H02P 9/30 - Arrangements for controlling electric generators for the purpose of obtaining a desired output by variation of field using discharge tubes or semiconductor devices using semiconductor devices
G01R 33/383 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using permanent magnets
H01F 27/42 - Circuits specially adapted for the purpose of modifying, or compensating for, electric characteristics of transformers, reactors or choke coils
H01H 36/00 - Switches actuated by change of magnetic field or of electric field, e.g. by change of relative position of magnet and switch, by shielding
H02K 55/06 - Dynamo-electric machines having windings operating at cryogenic temperatures of the homopolar type
H03K 17/92 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the use of specified components by the use, as active elements, of superconductive devices
H01F 13/00 - Apparatus or processes for magnetising or demagnetising
There is provided an electrical switch comprising a length of superconducting material. In some forms the electrical switch is configured to be controlled between a low-resistance state and a higher-resistance state by the selective application of one or more switching mechanisms. In the higher-resistance state, current flowing through the length of superconducting material may approach the critical current of the length of superconducting material, may be substantially equal to the critical current or may be greater than the critical current. In some forms, the length of superconducting material is a length of high temperature superconducting material. The switching mechanisms may comprise: heating the length of superconducting material; applying a magnetic field to the length of superconducting material; applying a time-varying magnetic field to create dynamic resistance and/or heat; and/or applying a time-varying magnetic field to a loop of superconducting material to create a screening current around the loop.
H01L 39/10 - Devices using superconductivity or hyperconductivity; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details characterised by the means for switching
H01L 39/16 - Devices switchable between superconductive and normal states
H03K 17/92 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the use of specified components by the use, as active elements, of superconductive devices
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
C07C 229/38 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
Disclosed are electrolyte compositions for electrochemical devices, where the electrolyte compositions comprise a microemulsion and where the microemulsion comprises an aqueous phase and a water-immiscible phase. Also disclosed are microemulsion electrolyte compositions for electrically rechargeable electrochemical energy storage devices, including ion batteries (such as lithium ion, sodium ion, magnesium ion, calcium ion, and aluminium ion batteries), redox flow batteries and supercapacitors.
LANDCARE RESEARCH NEW ZEALAND LIMITED (New Zealand)
VICTORIA LINK LTD (New Zealand)
Inventor
Garvey, Patrick
Jackson, Michael David
Linklater, Wayne Leslie
Abstract
The invention relates to mammalian attractants and to the use of such attractants in baits and traps for killing, capturing and/or monitoring mammalian targets; in particular mustelids.
A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
A01N 35/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio-analogues thereofDerivatives thereof, e.g. acetals
The invention provides compounds of the Formula (I) or the Formula (Ia) which are useful intermediates in the synthesis of potential antiviral drugs such as 3'-deoxy-3',4'-didehydro-cytidine triphosphate (ddhCTP).
Propulsion mechanisms, other than for land vehicles;
apparatus for the propulsion of spacecraft or aircraft,
thrusters, ion thrusters; electric generators,
superconducting generators; electric motors (other than for
land vehicles), superconducting motors; dynamos, flux pumps,
superconducting dynamos, flux pumps; bearings,
superconducting bearings. Apparatus and installations for heating or cooling; heating
and cooling apparatus for use in spacecraft or aircraft;
cryocooling apparatus; cryogenic apparatus; cryostats, other
than for laboratory use.
40.
ELECTRICITY DISTRIBUTION NETWORK FAULT DETECTION SYSTEM AND METHOD
An electricity distribution network fault detector 122 is provided. The fault detector may comprise a signal processor 124 configured to perform signal processing on magnetic field data, the magnetic field data representing at least one magnetic field generated by at least one electricity distribution line 112; a data selector 126 configured to receive transformed magnetic field data from the signal processor 124 and to select a time window of the received data; and a classifier 128 configured to receive at least one time window from the data selector 126 and to apply a classification to the at least one time window, the classification selected from a group of classifications.
(1) Electric and electromagnetic and chemical-electromagnetic hybrid and laser propulsion mechanisms, other than for land vehicles, namely, laser ablation propulsion mechanisms, magnetoplasmadynamic propulsion mechanisms; apparatus for the propulsion of spacecraft or aircraft, namely, rocket thrusters, ion rocket thrusters; electric generators, superconducting generators; electric motors and superconducting motors for spacecraft and aircraft; dynamos, electric flux pumps, superconducting dynamos; levitated disc bearings, superconducting disc bearings.
(2) Apparatus and installations for heating or cooling, namely, cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; heating and cooling apparatus for use in spacecraft or aircraft; cryocooling apparatus, namely, cryocoolers; cryogenic apparatus, namely, cryocoolers, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations; cryostats, other than for laboratory use.
Electric and electromagnetic and chemical-electromagnetic hybrid and laser propulsion mechanisms, other than for land vehicles, namely, laser ablation propulsion mechanisms, magnetoplasmadynamic propulsion mechanisms; electric generators, superconducting generators; electric motors other than for land vehicles, superconducting motors other than for land vehicles; dynamos, electromagnetic flux pumps, superconducting dynamos, electric flux pumps; levitated disc bearings, superconducting disc bearings Apparatus and installations for heating or cooling, namely cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; heating and cooling apparatus for use in spacecraft or aircraft, namely cryocoolers, electric resistive heaters, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations, thermal radiators; cryocooling apparatus, namely cryocoolers; cryogenic apparatus, namely cryocoolers, heat pipes being component parts of heating or cooling installations, thermal switches being component parts of heating or cooling installations, thermal buses and conduits being component parts of heating or cooling installations; cryostats, other than for laboratory use, namely cryostats for electromagnets, cryostats for electromagnetic detectors
43.
AGENTS TO PREVENT TISSUE DAMAGE FROM CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITION OF THE GUT-DAMAGING BACTERIAL TOXINS TCDA AND TCDB
Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
01 - Chemical and biological materials for industrial, scientific and agricultural use
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Catalysts; catalysts for use in chemical processes;
catalysts for use in the manufacture of industrial
chemicals; ammonia; ammonia water; ammonia for industrial
purposes; anhydrous ammonia; chemical preparations for
scientific purposes, other than for medical or veterinary
use; chemical preparations for use in industry; chemical
reagents for scientific purposes; chemicals for industrial
use; chemicals for use in industry and science; chemicals
for use in the purification of water; chemicals for use in
the treatment of water; chemicals used in agriculture;
ammonia [volatile alkali] for industrial purposes; volatile
alkali [ammonia] for industrial purposes; rare earth
compounds; rare earth nitrides. Processing of raw materials; production and processing of
fuels and of other sources of energy; application of thin
films on the surfaces of objects by means of chemical,
mechanical, thermal, thermomechanical, chemical vapor
deposition, physical vapor deposition and vacuum deposition
processes; application of thin films on the surfaces of
objects by means of chemical, mechanical, thermal,
thermomechanical, chemical vapour deposition, physical
vapour deposition and vacuum deposition processes;
processing of chemicals and petrochemicals; processing of
fuel materials; processing of fuels; processing of gas;
processing of materials; production of energy by power
plants; production of energy; production and generation of
ammonia; production and generation of ammonia using rare
earth materials; provision of information, consultancy and
advice in relation to the aforesaid services; consultancy in
the field of energy production. Development of industrial processes; industrial process
development; scientific research in the field of renewable
energy; scientific research in the field of energy;
consultancy in the field of chemistry; consultancy in the
field of energy efficiency; consultancy in the field of
industrial research; consultancy in the field of industrial
process development; provision of information, consultancy
and advice in relation to the aforesaid services.
01 - Chemical and biological materials for industrial, scientific and agricultural use
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Rare earth catalysts for use in chemical processes; catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; rare earth catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; chemical reagents for scientific purposes; chemicals for use in industrial processing; chemicals for use in industry and science; chemicals for use in the purification of water; chemicals for use in the treatment of water; ammonia in the nature of volatile alkali for industrial processing; volatile alkali in the nature of ammonia for industrial processing; rare earth compounds; rare earth nitrides Processing of raw materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials, rare earth nitrides; production and processing of fuels and of other sources of energy; application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapor deposition, physical vapor deposition and vacuum deposition processes; application of thin films of rare earth materials on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes; application of rare earth nitrides on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes; processing of chemicals and petrochemicals; processing of fuel materials; processing of fuels; processing of natural gas; processing of materials namely hydrogen, nitrogen, ammonia, rare earth materials, rare earth nitrides; production of energy by power plants; production of energy; production and generation of ammonia; production and generation of ammonia using rare earth materials; provision of information, consultancy and advice in relation to the aforesaid services Development of industrial processes in the field of ammonia manufacture; industrial process development field of ammonia manufacture; scientific research in the field of renewable energy; scientific research in the field of energy; consultancy in the field of chemistry; consultancy in the field of energy efficiency; consultancy in the field of industrial research; consultancy in the field of industrial process development; provision of information, consultancy and advice in the field of the foregoing services
01 - Chemical and biological materials for industrial, scientific and agricultural use
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Bio-chemical catalysts; catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; rare earth catalysts for use in the manufacture of ammonia, ammonia water, anhydrous ammonia; catalysts for use in the manufacture of industrial chemicals; ammonia volatile alkali for industrial processes; ammonia water; anhydrous ammonia; chemicals for use in the purification of water; chemicals for use in the treatment of water; chemicals used in agriculture; ammonia [volatile alkali] for industrial purposes; volatile alkali [ammonia] for industrial purposes; rare earth compounds; rare earth nitrides. (1) Processing of raw materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials and rare earth nitrides, production and processing of fuels and of other sources of energy, application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapor deposition, physical vapor deposition and vacuum deposition processes, application of thin films on the surfaces of objects by means of chemical, mechanical, thermal, thermomechanical, chemical vapour deposition, physical vapour deposition and vacuum deposition processes, processing of chemicals and petrochemicals, processing of fuel materials, processing of fuels, processing of gas, processing of materials in the nature of hydrogen, nitrogen, ammonia, rare earth materials and rare earth nitrides, production of energy by power plants, production of energy, production and generation of ammonia, production and generation of ammonia using rare earth materials, provision of information, consultancy and advice in relation to the aforesaid services, consultancy in the field of energy production.
(2) Development of industrial processes in the field of ammonia manufacture, industrial process development in the field of ammonia manufacture, scientific research in the field of renewable energy, scientific research in the field of energy, consultancy in the field of chemistry, consultancy in the field of energy efficiency, consultancy in the field of industrial research in relation to ammonia manufacture, consultancy in the field of industrial process development in relation to ammonia manufacture, provision of information, consultancy and advice in relation to the aforesaid services.
An optical fibre sensing system (300) with an incident light source (309), a wavelength spectrum interrogator (313), and an optical fibre (302) with a substantially continuous fibre Bragg grating (306). An upstream portion (318) of the optical fibre has an attenuation length to light to the interrogator (313) at a first equilibrium wavelength. A downstream portion (322) of the optical fibre reflects light to the interrogator (313) when a change in temperature and/or strain at the downstream portion (322) causes a portion of the fibre Bragg grating to reflect light to the interrogator (313) at a second wavelength and at a second intensity. A processor (315) is configured to analyse the reflected spectrum (314) to determine when a portion of the fibre Bragg grating (306) is experiencing a change in temperature and/or strain based on deviation in the reflected spectrum (314) from an initial peak corresponding to the initial wavelength.
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
G01K 1/16 - Special arrangements for conducting heat from the object to the sensitive element
G01K 11/3206 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres at discrete locations in the fibre, e.g. using Bragg scattering
H01F 6/02 - QuenchingProtection arrangements during quenching
49.
Inhibitors of DNMT1 as anticancer therapeutic agents
Provided herein are inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use for inhibiting DNA methyltransferase 1. The invention relates to compounds, pharmaceutical compositions, and methods for inhibiting DNA methyltransferase 1. The inhibitors are compounds of the general formula:
An asymmetric magnet for use in performing MRI of a patient's head. The magnet has a patient end. The magnet provides an offset imaging volume (35) in a recess with an isocentre that is positioned closer to the patient end than an opposite end. The magnet has at least three groups of coils (44, 45, 46) in a generally tapering arrangement. The magnet also has an additional group of coils (47). A first group of coils (44) overlaps the additional group of coils (47), such that a bottom portion (47″) of the additional group of coils (47) is positioned closer to the patient end of the magnet than a top portion (44′) of the first group of coils (44).
G01R 33/00 - Arrangements or instruments for measuring magnetic variables
G01R 33/34 - Constructional details, e.g. resonators
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
Disclosed are a cathode materials suitable for an aluminium ion battery, wherein the cathode materials comprise a main group element nitride, and an oxide of a main group element or an oxide of a element in Group 1 to 13. The nitride is preferably a 2-dimensional layered material. Preferably, the ratio of the main group element nitride to the oxide is between 5:95 and 95:5 (by weight).
H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
An aspect of the invention provides a method of performing a distributed task over a network comprising a plurality of nodes. The method comprises: a plurality of network nodes observing (300) data; applying a first linear code function to the data observed by at least one network node of the plurality of network nodes to obtain (302) at least one function output; applying errors (304) to the at least one function output; a query node selected from the network nodes performing (308) a mixing procedure to aggregate node observations to obtain a first set of aggregated values until a stopping criteria (306) is satisfied; applying (312) a second linear code function to the set of aggregated values to obtain a second set of aggregated values returned to their observed domain; and the query node outputting (314) the second set of aggregated values.
H04W 84/18 - Self-organising networks, e.g. ad hoc networks or sensor networks
H04W 72/02 - Selection of wireless resources by user or terminal
G16Y 20/00 - Information sensed or collected by the things
H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
54.
A PROCESS FOR LIGHTING AND COMPOSITING AN OBJECT INTO AN IMAGE
A process for representing light in a scene that includes receiving an image of the scene, which may only be a partial view of the scene. The image is applied to at least one convolutional neural network (CNN) that generates reflectance maps of the scene for respective roughness levels. The process can then select at least one of the reflectance maps based on a roughness level of an object in the image, and light and composite the object into the image using the selected at least one of the reflectance maps.
The present application relates to semiochemical-based lures for mammals, particularly mammalian pest species that are useful for monitoring, capturing and/or controlling mammals and to methods of using semiochemical-based lures for monitoring, capturing and/or controlling mammals, particularly mammalian pest species. The present application also relates to the use of semiochemical-based lures for monitoring, capturing and/or controlling mammals, particularly mammalian pest species. In some embodiments, semiochemical-based lures are useful for reducing the number of mammalian pest species in one or more designated target environments.
A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
A01N 35/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio-analogues thereofDerivatives thereof, e.g. acetals
A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
G01R 33/035 - Measuring direction or magnitude of magnetic fields or magnetic flux using superconductive devices
H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
H02H 7/00 - Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions
The invention relates to a superconducting electrical switch. The switch comprises two parallel branches of superconducting material in a loop, and a magnetic field generator which generates a time-varying magnetic field through the loop in a direction generally parallel to the axis of the loop. The magnetic field generator is selectively activated and de-activated to switch the electrical switch between a low-resistance state and a higher-resistance state. In the low-resistance state, there is no magnetic field through the loop and transport current flows through the loop. In the higher-resistance state, a magnetic field through the loop induces a screening current such that the sum of the transport current and the screening current is substantially equal to the critical current or is greater than the critical current of the superconducting material. The switch may be used in, for example, a rectifier or fault current limiter.
H01L 39/16 - Devices switchable between superconductive and normal states
G01R 33/035 - Measuring direction or magnitude of magnetic fields or magnetic flux using superconductive devices
H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
H02H 7/00 - Emergency protective circuit arrangements specially adapted for specific types of electric machines or apparatus or for sectionalised protection of cable or line systems, and effecting automatic switching in the event of an undesired change from normal working conditions
The invention relates to a stabilising head support for use by a patient during MRI scanning. The head support includes a shell and an inflatable bladder that is located at least partially within the shell. During use, the shell is located within an MRI magnet and the bladder is inflated about the patient's head to help hold the head steady during imaging.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A polymer composition for impregnating a high temperature superconductor (HTS) coil, the composition comprising: a polymer resin, a plurality of particles of a first filler material, and a plurality of particles of a second filler material; wherein the median particle size of the second filler material is less than the median particle size of the first filler material. The polymer composition may be used to prepare a polymer impregnated HTS coil having a predetermined turn-to-turn spacing. A property of the polymer composition may also be modified, for example, the coefficient of thermal contraction and/or resistivity of the composition. Also disclosed is a polymer impregnated HTS coil and a method for preparing the coil.
The present invention encompasses non-ribosomal peptides and non-ribosomal peptide synthetases, and the preparation and use thereof. Specifically encompassed are methods for preparing non-ribosomal peptide synthetases, methods for preparing non-ribosomal peptides from these enzymes, as well as polynucleotides used for producing these enzymes, libraries comprising these polynucleotides, and microbial strains comprising these polynucleotides.
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A modular and hierarchical DNA assembly platform for synthetic biology is described. This enabling technology, termed MIDAS (for Modular Idempotent DNA Assembly System), can precisely assemble multiple DNA fragments in a single reaction using a standardised assembly design. It can be used to build genes from libraries of sequence-verified, reusable parts and to assemble multiple genes in a single vector. We describe the design and use of MIDAS, and its application in the reconstruction of the metabolic pathway for production of paspaline, a key intermediate in the biosynthesis of a range of indole diterpenes—a class of economically important secondary metabolites produced by several species of filamentous fungi.
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists of Formula I. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
66.
COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS
This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.
The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/80 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi
C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
A01N 63/30 - Microbial fungiSubstances produced thereby or obtained therefrom
An aspect of the invention provides a classification system (100) configured to classify at least one data point within a data set (106). The system comprises a first machine learning model (110) in which is maintained a first plurality of data points associated to respective first labels; a second machine learning model (112) in which is maintained a second plurality of data points associated to respective second labels; and a (classifier 114). The classifier (114) is configured to: classify the at least one data point using the first machine learning model (110) to a first confidence level to determine at least one first classification label; responsive to the first confidence level having a value greater than or equal to a classification threshold value: classifying the at least one data point with the at least one first classification label to the first confidence level; and responsive to the first confidence level having a value of zero and/or the first confidence level having a value below the classification threshold value: classifying the at least one data point using the second machine learning model to a second confidence level to determine at least one second classification label, responsive to the first confidence level having a value less than the second confidence level: classifying the at least one data point with the at least one second classification label, and responsive to the first confidence level having a value greater than or equal to the second confidence level: classifying the at least one data point with the at least one first classification label to the second confidence level.
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Business management; business administration; business
services, namely business advice, business management,
business administration, business consultancy, and business
information services, all relating to technology
commercialisation and transfer, evaluation of technologies
and assessing commercial potential, and establishment of new
businesses and companies; business consultation, business
information and business advisory services, including, but
not limited to, such services provided in relation to
technology transfer, commercialisation of technology,
research and development of products and processes, and
intellectual property assessment; developing and
facilitating business networks, including, but not limited
to, connecting university researchers, staff and students
with business mentors and advisors; business networking and
career networking services; negotiation of commercial
transactions for third parties, including, but not limited
to, the negotiation of agreements, assignments, contracts,
deeds and licences; market analysis and market research
services; sponsorship search services; and advertising,
promotional, and marketing services, including, but not
limited to, such services relating to technology transfer,
commercialisation of technology, research and development of
products and processes, and intellectual property
assessment; business research and evaluations; providing
advice, consultancy, and information relating to the
foregoing. Charitable fundraising services and fundraising activities,
including, but not limited to, charitable fundraising for
research purposes, technology commercialisation and
transfer; financial sponsorship services, including, but not
limited to, charitable sponsorship of research into health,
medicine, biotechnology, energy, environment, materials
science, electronic devices and instrumentation,
engineering, and computer software; fund distribution
services; financial grant services; and providing
information and advice about charitable fundraising services
and activities, sponsorship services, fund distribution
services, and financial grant services; providing advice,
consultancy, and information relating to the foregoing. Education and training services, including, but not limited
to, capacity building of national and local governments in
the fields of good governance, education, and health;
english language training for officials; education and
training to enhance leadership and management skills;
education and training in relation to government and public
sector reform, digital government, education, health and
wellbeing, innovation, good governance, environmental
services, management, organisational structures, technology
commercialisation and transfer, business, entrepreneurship,
intellectual property, and other commercial activities;
teaching, mentoring and coaching services; arranging and
conducting of lectures, seminars, workshops, conferences,
colloquiums, congresses and symposiums, including, but not
limited to, in respect of topics relating to science and
research, business management, technology commercialisation,
intellectual property, and other commercial activities;
production of audio recordings, video recordings,
audio-visual recordings, multimedia, radio programmes,
television programmes and video film, including, but not
limited to, in respect of topics relating to technology
commercialisation and transfer, business, entrepreneurship,
intellectual property, and other commercial activities;
providing information and advice about education and
training services; and program design, providing advice,
consultancy, and information relating to the foregoing. Scientific and technological services and research and
design relating thereto; industrial analysis and industrial
research services; design and development of computer
hardware and software; research relating to science,
industry, and technology, including, but not limited to,
health research, medical research, biotechnology research,
energy research, environmental research, materials science
research, electronic device and instrumentation research,
engineering research, and computer software research;
technological research; co-operative scientific and
industrial research, including, but not limited to,
cooperation amongst researchers and interaction between
research and industry sectors; industrial research of new
products and processes; scientific, industrial, and
technology research and development services for others;
preparation of reports relating to research, including, but
not limited to, reports regarding the outcomes of medical
and scientific research; and providing information and
advice about scientific, industrial, and technology research
services; providing advice, consultancy, and information
relating to the foregoing. Licensing of research and development activities; advisory
services relating to intellectual property rights,
protection and licensing; advisory services and consultancy
relating to intellectual property, technology transfer and
research and development; arranging for the provision of
legal services; legal services relating to the creation,
registration, and exploitation of intellectual property
rights; information services relating to intellectual
property matters; intellectual property consultancy;
investigations in relation to intellectual property;
licensing of intellectual property rights and research and
development; management of intellectual property; legal
research; research relating to intellectual property;
services for the exploitation of intellectual property
rights and inventions; providing advice, consultancy, and
information relating to the foregoing.
09 - Scientific and electric apparatus and instruments
Goods & Services
Batteries; electrical cells; electric accumulators; electric
actuators; electric power supply units; electric power
storage apparatus; rechargeable batteries; aluminium-ion
batteries; anodes; cathodes; battery cables, chargers,
holders, leads, packs, plates and terminals; apparatus and
instruments for conducting, switching, transforming,
accumulating, regulating or controlling the use of
electricity; scientific apparatus and instruments; battery
cell packs; drone batteries; vehicle batteries; batteries
for lighting; mobile phone batteries; grid storage
batteries; residential batteries; consumer electronic
batteries; e-bike batteries; micromobility batteries; boat
batteries; and ship batteries.
Disclosed are electrolyte compositions for electrochemical devices, where the electrolyte compositions comprise a microemulsion and where the microemulsion comprises an aqueous phase and a water-immiscible phase. Also disclosed are microemulsion electrolyte compositions for electrically rechargeable electrochemical energy storage devices, including ion batteries (such as lithium ion, sodium ion, magnesium ion, calcium ion, and aluminium ion batteries), redox flow batteries and supercapacitors.
The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical additives for insecticides; chemical additives for
pesticides; chemical additives for use in the manufacture of
pharmaceuticals; active chemical ingredients for use in the
manufacture of insecticides; active chemical ingredients for
use in the manufacture of pesticides; active chemical
ingredients for use in the manufacture of pharmaceuticals;
active chemical ingredients for use in the manufacture of
plant protection agents; catalysts for use in biochemical
processes; catalysts for chemical and biochemical processes;
chemicals for use in biotechnological manufacturing
processes; chemicals for use in biotechnological product
development; enzymes derived from biotechnological processes
for use in industry; nucleic acids for scientific purposes;
nucleic acids for synthetic purposes; preparations for
protecting plants against pests or pathogens. Insecticides; pesticides; fungicides; parasiticides;
chemical preparations for treating diseases affecting crops;
chemical preparations for treating diseases affecting
plants; pharmaceuticals; active pharmaceutical ingredients
and active veterinary ingredients for the treatment of human
and animal diseases and medical conditions; antibiotics. Scientific research and development; scientific and
technological services; scientific and technological
services and research and design relating thereto;
scientific and technological services and research and
development relating thereto; scientific and medical
research and development; scientific research in the field
of genetics and genetic engineering; genetic engineering
services; oligonucleotide synthesis; agrochemical research
and development; biological research and analysis;
biological research and development; biological synthesis;
biotechnological research; synthesis of active chemical
ingredients for use in the manufacture of insecticides,
pesticides, plant protection agents and pharmaceuticals;
biological, pharmaceutical, veterinary and medical research.
36 - Financial, insurance and real estate services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Business management; business administration; business services, namely, business advice, business management, business administration, business consultancy, and business information services, all relating to technology commercialisation and transfer, evaluation of technologies and assessing commercial potential, and establishment of new businesses and companies; business consultation, business information and business advisory services, in particular, such services provided in relation to technology transfer, commercialisation of technology, research and development of products and processes, and intellectual property assessment; developing and facilitating business networks by providing business networking, in particular, for university researchers, staff and students with business mentors and advisors; business networking and career networking services; negotiation of commercial transactions for third parties, in particular, the negotiation of agreements, assignments, contracts, deeds and licences; market analysis and market research services; sponsorship search services; and advertising, promotional, and marketing services, in particular, such services relating to technology transfer, commercialisation of technology, research and development of products and processes, and intellectual property assessment; business research and evaluations; providing advice, consultancy, and information relating to the foregoing Charitable fundraising services and organizing fundraising activities for the benefit of research purposes, technology commercialisation and transfer; sponsorship services, in particular, charitable sponsorship of research into health, medicine, biotechnology, energy, environment, materials science, electronic devices and instrumentation, engineering, and computer software; charitable fund distribution services; financial grant services for research into health, medicine, biotechnology, energy, environment, materials science, electronic devices and instrumentation, engineering and computer software; and providing information and advice about charitable fundraising services and charitable fundraising activities, charitable sponsorship services, charitable fund distribution services, and financial grant services; providing advice, consultancy, and information relating to the foregoing Education, namely, providing seminars, workshops and training in particular, on capacity building of national and local governments in the fields of good governance, education, and health; English language training for officials; education, namely, providing seminars, workshops and training in the field of enhancing leadership and management skills; education, namely, providing seminars, workshops and training in the field of government and public sector reform, digital government, business education, health and wellbeing, innovation, good governance, environmental services, management, organisational structures, technology commercialisation and transfer, business, entrepreneurship, intellectual property, and other commercial activities; teaching, mentoring and coaching services in the field of entrepreneurship; arranging and conducting of lectures, seminars, workshops, conferences, colloquiums, congresses and symposiums, in particular, in the field of science and research, business management, technology commercialisation, intellectual property, and other commercial activities; production of audio recordings, video recordings, audio-visual recordings, multimedia, radio programmes, television programmes and video film, in particular, on topics relating to technology commercialisation and transfer, business, entrepreneurship, intellectual property, and other commercial activities; providing information and advice about education and training services; program design in the nature of developing curriculum for educators; providing advice, consultancy, and information relating to the foregoing Scientific and technological services, namely, research and design in the fields of science, medicine and engineering; industrial analysis and industrial research in the field of science, medicine and engineering; design and development of computer hardware and software; research in the fields of science, industry, and technology, in particular, health research, medical research, biotechnology research, energy research, environmental research, materials science research, electronic device and instrumentation research, engineering research, and computer software research; technological research in the fields of science, medicine and engineering; co-operative scientific research and industrial research in the fields of medicine and engineering featuring cooperation amongst researchers and interaction between research and industry sectors; industrial research of new products and processes; scientific, industrial, and technology research and development of new products for others; preparation of medical and scientific reports relating to research, in particular, reports regarding the outcomes of medical and scientific research; providing information and advice about scientific research, industrial research and technology research in the fields of biology, chemistry, biomedicine and medicine; providing advice, consultancy, and information relating to the foregoing Licensing of intellectual property rights for new product research and development activities; advisory services relating to intellectual property rights, protection and licensing; legal advisory services and legal consultancy relating to intellectual property, technology transfer and research and development; arranging for the provision of legal services, namely, legal document preparation services and legal advisory services; establishment and exploitation in the nature of legal research in the field of intellectual property rights; information services relating to intellectual property matters; intellectual property consultancy; investigations in relation to intellectual property, namely, intellectual property watch services; licensing of intellectual property rights, intellectual property research and intellectual property development; licensing of software for management of intellectual property; legal research; legal research relating to intellectual property; legal research services for the exploitation of intellectual property rights and inventions; providing advice, consultancy, and information relating to the foregoing
01 - Chemical and biological materials for industrial, scientific and agricultural use
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical additives for insecticides; chemical additives for
pesticides; chemical additives for use in the manufacture of
pharmaceuticals; active chemical ingredients for use in the
manufacture of insecticides; active chemical ingredients for
use in the manufacture of pesticides; active chemical
ingredients for use in the manufacture of pharmaceuticals;
active chemical ingredients for use in the manufacture of
plant protection agents; catalysts for use in biochemical
processes; catalysts for chemical and biochemical processes;
chemicals for use in biotechnological manufacturing
processes; chemicals for use in biotechnological product
development; enzymes derived from biotechnological processes
for use in industry; nucleic acids for scientific purposes;
nucleic acids for synthetic purposes; preparations for
protecting plants against pests or pathogens. Scientific research and development; scientific and
technological services; scientific and technological
services and research and design relating thereto;
scientific and technological services and research and
development relating thereto; scientific and medical
research and development; scientific research in the field
of genetics and genetic engineering; genetic engineering
services; oligonucleotide synthesis; agrochemical research
and development; biological research and analysis;
biological research and development; biological synthesis;
biotechnological research; synthesis of active chemical
ingredients for use in the manufacture of insecticides,
pesticides, plant protection agents and pharmaceuticals;
biological, pharmaceutical, veterinary and medical research.
A magnet (7) for use in an apparatus (1) for performing magnetic resonance imaging (MRI) of a patient's head is an asymmetric magnet (7) comprising a plurality of coils (45, 46, 47) that are aligned along a cylindrical axis (29) to provide a magnetic field on the cylindrical axis (29). The magnet (7) has a patient end (23) arranged to be positioned adjacent or against a patient's shoulders with the patient's shoulders outside the magnet (7). The magnet has a recess (27) for receipt of the patient's head and extending into the magnet (7) from the patient end (23). The magnet (7) is configured to provide an imaging volume (35) that is positioned along the cylindrical axis (29) of the magnet (7) in the recess (27), and at least a major part of the imaging volume (35) has a substantially linear non-zero magnetic field gradient along the cylindrical axis (29).
G01R 33/381 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets
G01R 33/38 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01R 33/3815 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets with superconducting coils, e.g. power supply therefor
G01R 33/421 - Screening of main or gradient magnetic field
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
79.
Rare earth nitride structures and devices and method for removing a passivating capping
The present invention concerns a structure or device comprising a rare earth nitride material, and a removable capping for passivating the rare earth nitride material.
H01L 43/02 - Devices using galvano-magnetic or similar magnetic effects; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof - Details
H01F 1/03 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials characterised by their coercivity
Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical compositions, methods for inhibiting DNA methyltransferase 1, and methods for treating cancer. The inhibitors are compounds of the general formula.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
An optical fibre sensing system (300) with an incident light source (309), a wavelength spectrum interrogator (313), and an optical fibre (302) with a substantially continuous fibre Bragg grating (306). An upstream portion (318) of the optical fibre has an attenuation length to light to the interrogator (313) at a first equilibrium wavelength. A downstream portion (322) of the optical fibre reflects light to the interrogator (313) when a change in temperature and/or strain at the downstream portion (322) causes a portion of the fibre Bragg grating to reflect light to the interrogator (313) at a second wavelength and at a second intensity. A processor (315) is configured to analyse the reflected spectrum (314) to determine when a portion of the fibre Bragg grating (306) is experiencing a change in temperature and/or strain based on deviation in the reflected spectrum (314) from an initial peak corresponding to the initial wavelength.
G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
An asymmetric magnet for use in performing MRI of a patient's head. The magnet has a patient end. The magnet provides an offset imaging volume (35) in a recess with an isocentre that is positioned closer to the patient end than an opposite end. The magnet has at least three groups of coils (44, 45, 46) in a generally tapering arrangement. The magnet also has an additional group of coils (47). A first group of coils (44) overlaps the additional group of coils (47), such that a bottom portion (47") of the additional group of coils (47) is positioned closer to the patient end of the magnet than a top portion (44') of the first group of coils (44).
01 - Chemical and biological materials for industrial, scientific and agricultural use
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical additives for insecticides; chemical additives for pesticides; active chemical ingredients for use in the manufacture of insecticides; active chemical ingredients for use in the manufacture of pesticides; active chemical ingredients for use in the manufacture fungicides and parasiticides; active chemical ingredients for use in the manufacture of plant protection agents; genetically engineered catalysts for use in biochemical processes; genetically engineered catalysts for chemical and biochemical processes; chemicals for use in genetically engineered biotechnological manufacturing processes; chemicals for use in genetically engineered biotechnological product development; genetically engineered enzymes derived from biotechnological processes for use in industry, namely in animal health, and crop protection; nucleic acids for scientific purposes, for use in animal health and crop protection; nucleic acids for synthetic purposes, animal and health, crop protection, and pharmaceuticals not for medical purposes; preparations for protecting plants against pests or pathogens Scientific research and development, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; scientific and technological services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and,crop protection; scientific and technological services and research and design relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; scientific and technological services and research and development relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection scientific and medical research and development, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; genetic engineering services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health and crop protection; agrochemical research and development; biological research and analysis; biological and chemical research services especially in the fields of chemical and biological synthesis of compounds, in particular of biomolecules, and the purification methods of synthesis compounds, in particular biomolecules; genetically engineered biological synthesis of active chemical ingredients for use in the manufacture of insecticides, pesticides, and plant protection agents; biological veterinary and medical research
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical additives for insecticides; chemical additives for pesticides; chemical additives for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of insecticides; active chemical ingredients for use in the manufacture of pesticides; active chemical ingredients for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of plant protection agents; catalysts for use in biochemical processes; catalysts for chemical and biochemical processes; chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; nucleic acids for scientific purposes; nucleic acids for synthetic purposes; preparations for protecting plants against pests or pathogens Insecticides; pesticides; fungicides; parasiticides; chemical preparations for treating diseases affecting crops; chemical preparations for treating diseases affecting plants; pharmaceuticals for the treatment of blood feeding arthropods, cancer, bacterial infections, and influenza infection; active pharmaceutical ingredients and active veterinary ingredients for the treatment of human and animal diseases and medical conditions namely for the treatment of blood feeding arthropods, cancer, bacterial infections, and influenza infection; antibiotics Scientific research and development; scientific and technological services, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and technological services and research and design relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell [ ines ] * lines * or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and technological services and research and development relating thereto, namely, genetics and genetic engineering of microorganisms, mammalian cell lines or plant cell lines for use in animal health, crop protection and pharmaceuticals; scientific and medical research and development; scientific research in the field of genetics and genetic engineering; genetic engineering services; agrochemical research and development; biological research and analysis; biological research and development; biological synthesis; biotechnological research; synthesis of active chemical ingredients for use in the manufacture of insecticides, pesticides, plant protection agents and pharmaceuticals; biological, pharmaceutical, veterinary and medical research
The present invention relates generally to methods of using nalmefene for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalmefene for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalmefene for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A rendering process and system that may be used to composite virtual objects in panoramic video to provide a virtual reality and augmented reality experience. The process includes receiving low dynamic range (LDR) video data, e.g. 360° video; generating radiance maps, such as diffuse and specular maps, from the LDR data; inverse tone mapping the LDR data of the maps to generate high dynamic range (HDR) data for the maps; and receiving at least one virtual object and applying image based lighting (IBL) to the virtual object using the HDR data of the maps. A perceptually based threshold is also applied to radiance maps to detect prominent pixels, and using the prominent pixels as salient lights for image based shadowing (IBS) associated the virtual object. Objects are composited 360° video in real time using IBL and IBS without precomputation allowing user interaction with the objects.
An optical system for narrowing the bandwidth of a beam of incident radiation comprises an optical mixing unit configured to receive a first beam of radiation and a second beam of radiation. The first and second beams are spatially chirped and the first beam is inverted relative to the second beam. The optical mixing unit comprises an optical mixing member comprising a nonlinear optical medium to mix the first and second beams into an output beam having a narrower bandwidth than the beam of incident radiation.
The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.
A system for determining a relative position associated to a first receiver and a second receiver includes a code module 402 configured to receive location data associated to the first receiver, receive location data associated to the second receiver, and determine a first estimate relative position associated to the first receiver and the second receiver; a float module 404 configured to determine a second estimate relative position associated to the first receiver and the second receiver at least partly from the first estimate relative position; a fix module 406 configured to determine a third estimate relative position associated to the first receiver and the second receiver at least partly from the second estimate relative position; and a sidereal module 408 configured to determine a fourth estimate relative position associated to the first receiver and the second receiver at least partly from the third estimate relative position.
The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
The invention relates to branched trehalose glycolipids of Formula (I) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
A computer-implemented method to capture and detect clusters in, or determined by, a set V of discrete digital data comprising; computing, from the set V, an abstract separation system ASS that consists of a finite set S, whose elements are called separations; of a predetermined transitive, antisymmetric and reflexive order relation ≤ on S; and of an order-reversing involution *: S→S, that is, a mapping s→s* with the property that, (s*)*=s and that r≤s implies s*
G06V 10/62 - Extraction of image or video features relating to a temporal dimension, e.g. time-based feature extractionPattern tracking
G06F 18/23213 - Non-hierarchical techniques using statistics or function optimisation, e.g. modelling of probability density functions with fixed number of clusters, e.g. K-means clustering
A rendering process, including receiving an input image and applying a light feature detection process to the input image to generate light feature parameters for the input image; accessing a radiance map database using the light feature parameters to select a radiance map; and rendering an output image with a virtual scene and lighting the output image using the selected radiance map. The light feature parameters are of a dominant light feature vector representing dominant lights and an ambient light feature vector representing ambient light of the input image. A light feature index for the radiance map database is generated by processing an input panoramic image using a light feature detection process to generate the light feature parameters associated with the input panoramic image; and using the light feature parameters as the index for the panoramic image in the database. The database provides an illumination space comprising the light feature index.
Nodulisporic acids (NAs) comprise a group of indole diterpenes known for their potent insecticidal activities; however, biosynthesis of NAs by its natural producer, Hypoxylon pulicicidum (Nodulisporium sp.) is exceptionally difficult to achieve. The identification of genes responsible for NA production could enable biosynthetic pathway optimization to provide access to NAs for commercial applications. Obtaining useful quantities of NAs using published fermentations methods is challenging, making gene knockout studies an undesirable method to confirm gene function. Alternatively, heterologous gene expression of H. pulicicidum genes in a more robust host species like Penicillium paxilli provides a way to rapidly identify the function of genes that play a role in NA biosynthesis. In this work, we identified the function of four secondary-metabolic genes necessary for the biosynthesis of nodulisporic acid F (NAF) and reconstituted these genes in the genome of P. paxilli to enable heterologous production of NAF in this fungus.
C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
A modular and hierarchical DNA assembly platform for synthetic biology is described. This enabling technology, termed MIDAS (for Modular Idempotent DNA Assembly System), can precisely assemble multiple DNA fragments in a single reaction using a standardised assembly design. It can be used to build genes from libraries of sequence-verified, reusable parts and to assemble multiple genes in a single vector. We describe the design and use of MIDAS, and its application in the reconstruction of the metabolic pathway for production of paspaline, a key intermediate in the biosynthesis of a range of indole diterpenes — a class of economically important secondary metabolites produced by several species of filamentous fungi.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
Nodulisporic acids (NAs) comprise a group of indole diterpenes known for their potent insecticidal activities; however, biosynthesis of NAs by its natural producer, Hypoxylon pulicicidum (Nodulisporium sp.) is exceptionally difficult to achieve. The identification of genes responsible for NA production could enable biosynthetic pathway optimization to provide access to NAs for commercial applications. Obtaining useful quantities of NAs using published fermentations methods is challenging, making gene knockout studies an undesirable method to confirm gene function. Alternatively, heterologous gene expression of H. pulicicidum genes in a more robust host species like Penicillium paxilli provides a way to rapidly identify the function of genes that play a role in NA biosynthesis. In this work, we identified the function of four secondary-metabolic genes necessary for the biosynthesis of nodulisporic acid F (NAF) and reconstituted these genes in the genome of P. paxilli to enable heterologous production of NAF in this fungus.
C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
A01N 63/04 - Microbial fungi; Substances produced thereby or obtained therefrom
The invention relates to peptide conjugates of Formula (I). The peptide conjugates of the invention have activity as MAIT agonists. The peptide conjugates of the invention also enhance immune responses and therefore are effective vaccines and vaccine adjuvants. The invention also relates to methods and uses of such conjugates.
C07D 239/545 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
